
Twelve years of multiples investors have paid for Aarey Drugs & Pharmaceuticals Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Aarey Drugs & Pharmaceuticals Ltd trades at a P/E of 45.37×.
Twelve years of audited numbers for Aarey Drugs & Pharmaceuticals Ltd, switchable between annual and quarterly views, consolidated or standalone.
Aarey Drugs & Pharmaceuticals Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹188.698 Cr and reported EPS of ₹1.47.
Why someone would buy Aarey Drugs & Pharmaceuticals Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
No strengths or opportunities on record.
No weaknesses or threats on record.
Trim if P/E re-rates above 59. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Aarey Drugs & Pharmaceuticals Ltd is highlighted for quick read-across.
| Company Name |
|---|
Aarey Drugs & Pharmaceuticals LtdCurrent Stock |
Aarti Drugs Ltd |
Aarti Pharmalabs Ltd |
Ajanta Pharma Ltd |
Akums Drugs & Pharmaceuticals Ltd |
Albert David Ltd |
Alivus Life Sciences Ltd |
Alkem Laboratories Ltd |
Alpa Laboratories Ltd |
Amrutanjan Health Care Ltd |
Alembic Pharmaceuticals Ltd |
Astrazeneca Pharma India Ltd |
Aurobindo Pharma Ltd |
Bafna Pharmaceuticals Ltd |
Bajaj Healthcare Ltd |
Bal Pharma Ltd |
Biocon Ltd |
Biofil Chemicals & Pharmaceuticals Ltd |
Bliss GVS Pharma Ltd |
Blue Jet Healthcare Ltd |
Brooks Laboratories Ltd |
Caplin Point Laboratories Ltd |
Cipla Ltd |
Cohance Lifesciences Ltd |
Concord Biotech Ltd |
Dishman Carbogen Amcis Ltd |
Divis Laboratories Ltd |
Dr Reddys Laboratories Ltd |
Emcure Pharmaceuticals Ltd |
ERIS Lifesciences Ltd |
FDC Ltd |
Gland Pharma Ltd |
Glaxosmithkline Pharmaceuticals Ltd |
Glenmark Pharmaceuticals Ltd |
Granules India Ltd |
Gufic BioSciences Ltd |
Haleos Labs Limited |
Hester Biosciences Ltd |
Hikal Ltd |
Indoco Remedies Ltd |
Ind-Swift Laboratories Ltd |
Innova Captab Ltd |
IOL Chemicals & Pharmaceuticals Ltd |
Ipca Laboratories Ltd |
Jagsonpal Pharmaceuticals Ltd |
J B Chemicals & Pharmaceuticals Ltd |
Jubilant Pharmova Ltd |
Kilitch Drugs (India) Ltd |
Kopran Ltd |
Krebs Biochemicals & Industries Ltd |
Lasa Supergenerics Ltd |
Laurus Labs Ltd |
Lincoln Pharmaceuticals Ltd |
Lupin Ltd |
Lyka Labs Ltd |
Mangalam Drugs and Organics Ltd |
Mankind Pharma Ltd |
Marksans Pharma Ltd |
Medicamen Biotech Ltd |
Medico Remedies Ltd |
Morepen Laboratories Ltd |
Natco Pharma Ltd |
Nectar Lifescience Ltd |
Neuland Laboratories Ltd |
NGL Fine Chem Ltd |
OneSource Specialty Pharma Ltd |
Orchid Pharma Ltd |
Ortin Global Ltd |
Panacea Biotec Ltd |
Pfizer Ltd |
Procter & Gamble Health Ltd |
Piramal Pharma Ltd |
RPG Life Sciences Ltd |
Sai Life Sciences Ltd |
Sanofi India Ltd |
Sanofi Consumer Healthcare India Ltd |
Senores Pharmaceuticals Ltd |
Shilpa Medicare Ltd |
Sigachi Industries Ltd |
SMS Pharmaceuticals Ltd |
Solara Active Pharma Sciences Ltd |
Sun Pharma Advanced Research Company Ltd |
Strides Pharma Science Ltd |
Sun Pharmaceutical Industries Ltd |
Supriya Lifescience Ltd |
Syncom Formulations (India) Ltd |
Themis Medicare Ltd |
Torrent Pharmaceuticals Ltd |
Unichem Laboratories Ltd |
Valiant Laboratories Ltd |
Venus Remedies Ltd |
Vineet Laboratories Ltd |
Viyash Scientific Ltd |
Wanbury Ltd |
Windlas Biotech Ltd |
Wockhardt Ltd |
Zim Laboratories Ltd |
Zydus Lifesciences Ltd |
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Aarey Drugs & Pharmaceuticals Ltd — derived from the live tape, not yesterday's close.
Aarey Drugs & Pharmaceuticals Ltd last traded at ₹90.51 with an intraday range of ₹90.44–₹96 — live indicator, pivot and CPR signals below.
Standard pivot — most widely referenced.
| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 105.31 | +14.80 | +16.36% |
| R3 | 99.75 | +9.24 | +10.21% |
| R2 | 97.88 | +7.37 | +8.14% |
| R1 | 94.19 | +3.68 | +4.07% |
| PIVOT | 92.32 | 1.81 | 2.00% |
| CURRENT | 90.51 | — | — |
| S1 | 77.51 | -13.00 | -14.36% |
| S2 | 83.07 | -7.44 | -8.22% |
| S3 | 86.76 | -3.75 | -4.15% |
| S4 | 88.63 | -1.88 | -2.07% |
AAREYDRUGS is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ~
Trading Below opening range, showing Bearishness
Daily traded volume and delivery percentage for Aarey Drugs & Pharmaceuticals Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Aarey Drugs & Pharmaceuticals Ltd stood at 60.9% of traded volume, against a 20-day average of 66.6%.
Filings Aarey Drugs & Pharmaceuticals sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Every dividend, stock split and bonus issue Aarey Drugs & Pharmaceuticals has declared, sequenced by announce and record date.
Aarey Drugs & Pharmaceuticals corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Disclosed business segments at Aarey Drugs & Pharmaceuticals with their share of revenue and profit, switchable between consolidated and standalone reporting.
Aarey Drugs & Pharmaceuticals discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
What Aarey Drugs & Pharmaceuticals Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Aarey Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals industry under the Health Care sector, listed as NSE: AAREYDRUGS, BSE: 524412.

Aarey Drugs & Pharmaceuticals Limited is an Indian company established in 1990 and headquartered in Mumbai. Its core business revolves around the manufacturing and sale of a diverse range of chemical products, primarily targeting the pharmaceutical and industrial sectors.
A significant portion of Aarey's business focuses on the production and supply of Active Pharmaceutical Ingredients (APIs). These APIs, which are crucial components in the manufacturing of various pharmaceuticals, include key substances such as metformin HCL, mefenamic acid, and doxophylline. These products are directly sold to pharmaceutical formulation manufacturers and exporters, playing a vital role in the broader pharmaceutical supply chain.
Beyond APIs, Aarey also produces and sells a wide array of intermediates and specialty chemicals utilized in various industrial applications. This extensive catalog encompasses a diverse range of chemical compounds, including mono methyl and die methyl urea, ortho para nitro anisole, 2 bromomethyl 1,3 dioxalane, and uracile. The company’s industrial chemical offerings extend to solvents, aromatic chemicals, acids, chlor alkalies, glycols and glycol ethers, fiber intermediates, acetates and esters, chlorinated solvents, alcohols, ketones, amines, oleochemicals, olefines, phosphates, fertilizers, and monomers.
In addition to its manufacturing operations, Aarey Drugs engages in the trading of industrial solvents and chemicals, further expanding its reach and product portfolio within the chemical industry. This trading activity complements its manufacturing business, providing a broader service offering to its customers and contributing to the overall revenue streams of the company.
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
The current share price of Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS) is ₹90.51. Today, the stock has declined by ₹4.68 (4.92%), trading in a range of ₹90.44 to ₹96. The stock opened at ₹94.1 with a trading volume of 2,20,098 shares.
Aarey Drugs & Pharmaceuticals Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹188.7 crores, P/E ratio of 45.37, ROE of 1.51%, and ROCE of 6.00%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS) is ₹100, while the 52-week low is ₹47.76. Currently trading at ₹90.51, the stock is 81.8% away from its 52-week low and 9.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Aarey Drugs & Pharmaceuticals Ltd stock at ₹90.51 depends on multiple factors. The stock is currently trading with a P/E ratio of 45.37 and P/B ratio of N/A. Today's performance shows a loss of 4.92%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Aarey Drugs & Pharmaceuticals Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹90.51, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Aarey Drugs & Pharmaceuticals Ltd's key financial metrics include: P/E Ratio: 45.37, P/B Ratio: N/A, ROE: 1.51%, ROCE: 6.00%, Dividend Yield: 0.00%, EPS: ₹1.47, Book Value: ₹48.67, Debt-to-Equity: 0.25, and Current Ratio: N/A. The company's market cap stands at ₹188.7 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Aarey Drugs & Pharmaceuticals Ltd stock opened at ₹94.1 and is currently trading at ₹90.51, showing a decline of ₹4.68 (4.92%). The intraday high is ₹96 and low is ₹90.44. The trading volume stands at 2,20,098 shares, indicating moderate market participation today.
Aarey Drugs & Pharmaceuticals Ltd has a Price-to-Earnings (P/E) ratio of 45.37, which means investors are willing to pay ₹45.37 for every ₹1 of earnings. With an EPS of ₹1.47, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Peers, sector trends, screeners and strategy playbooks contextual to this stock.